TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01342211

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo monthly during treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Statin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Intravenous 10mg/mL based on weight monthly during treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Intravenous 10mg/mL based on weight monthly during treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Intravenous 10mg/mL based on weight monthly during treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Satin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Intravenous 10mg/mL based on weight monthly during treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
Study: NCT04324411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus and ATRA
Description: sirolimus (serum concentration 4-10ng/ml) and ATRA 20mg bid
Study: NCT03703427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Oral, 500 Mg
Description: 1250mg/m2，d1-d14，q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate Oral
Description: 60mg/m2，d1；d8；q3w
Study: NCT01977989

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Powder
Description: For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
Study: NCT00118417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonazepam
Description: Participants will receive clonazepam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Participants will receive sertraline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: Participants will receive sertraline.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Participants will receive cognitive behavioral therapy
Study: NCT00400166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Mentor
Description: Provided Recovery Mentor services
Study: NCT04112719

Intervention type: OTHER
Intervention: supine position
Description: The patient will be placed in a supine position. Changes in cardiac output will be measured.

Intervention type: OTHER
Intervention: 15 degrees lateral tilt
Description: The patient will be placed in 15 degrees lateral tilt position. Changes in cardiac output will be measured.

Intervention type: OTHER
Intervention: 30 degrees lateral tilt
Description: The patient will be placed in 30 degrees lateral tilt position. Changes in cardiac output will be measured.
Study: NCT02206633

Intervention type: DEVICE
Intervention: Hydration Monitor
Description: Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
Study: NCT03894683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 10 mg
Description: Melatonin tablets (10 mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets manufactured the same as melatonin tablets
Study: NCT01244893

Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Advance Plus prePQ
Description: silicone hydrogel contact lens manufactured prior to equipment process qualification activities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Advance Plus prePQ
Description: silicone hydrogel contact lens manufactured prior to equipment process qualification activities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Advance Plus postPQ
Description: silicone hydrogel contact lens manufactured after equipment process qualification activities.

Intervention type: DEVICE
Group type: OTHER
Intervention: Acuvue Advance Plus postPQ
Description: silicone hydrogel contact lens manufactured after equipment process qualification activities.
Study: NCT02047032

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: solifenacin
Description: Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PFMT
Description: Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
Study: NCT01635504

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin A
Description: Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
Study: NCT01558804

Intervention type: OTHER
Intervention: Identifying group A strep carriers
Description: At study entry, at 14 days, and if follow up is positive, again in 14-21 days: Standard culture for GAS and analysis of mRNA.
Study: NCT03788252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renamezin
Description: 7 capsules once, three times a day, for 48 weeks
Study: NCT04334967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Treatment arm medication will be administered on an outpatient basis. Due to the emergent health crisis, study drug will be delivered to patients by institution staff or contract courier using a non-contact protocol.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Control arm supplement will be administered on an outpatient basis. Due to the emergent health crisis, study supplies will be delivered to patients by institution staff or contract courier using a non-contact protocol.
Study: NCT04648397

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic load, high fibrous product
Description: Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low glycaemic load, high fibrous product
Description: Test-lunch of 370 grams of chickpeas, seasoned with a herb- and spice mix to increase palatability. Glycaemic load 18.5. Consumed in duplicate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycaemic load, low fibrous product
Description: Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High glycaemic load, low fibrous product
Description: Test-lunch of 257 grams of brown rice, seasoned with rice-oil and a herb- and spice mix to increase palatability. Glycaemic load 44.9. Consumed in duplicate.
Study: NCT04540913

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RHA 3
Description: Investigational Product, RHA® 3 is a viscoelastic, sterile, non-pyrogenic, clear, colorless, homogenous, and biodegradable gel implant. It is formulated with sodium hyaluronic acid (NaHA) at a concentration of 23 mg/g obtained from bacterial fermentation using the Streptococcus equi bacterial strained, crosslinked with 1,4 butanediol diglycidyl ether (BDDE) and reconstituted in a physiological buffer (pH 7.3). RHA® 3 also contains 0.3% lidocaine hydrochloride to reduce pain on injection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane-L
Description: Comparator Product, Restylane-L is a gel of hyaluronic acid generated by Streptococcus species of bacteria, chemically crosslinked with BDDE, stabilized and suspended in phosphate buffered saline at pH=7 and concentration of 20 mg/mL with 0.3% lidocaine.
Study: NCT03553693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RAPID-VL study intervention
Description: * Viral load (VL) ordering flowsheet with periodic health facility performance feedback~* Rapid near-point-of-care VL testing and telephone delivery of results~* Structured VL counseling package
Study: NCT04823013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high power pain threshold ultrasound which the dose was kept constant
Description: Participants in HPPT-US 1 group received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, and then moved the US transducer in a circle without the change of the intensity for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high power pain threshold ultrasound which the dose reduced to one half
Description: Participants in HPPT-US 2 group also received the HPPT-US treatment. The intensity was gradually increased from 0.5 W/cm² to the pain threshold level at which the patient verbally reported the pain. The therapist kept the intensity at that level for 5 s, then reduced the dose half and moved the US transducer in a circle for 15 s. The procedure was repeated 3 times. The patients were asked whether serious pain or any abnormal sensation was felt during HPPT-US. The intensity was varied from 0.5 to 1.2 W/ cm².

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ischemic compression
Description: Participants in IC group received ischemic compression therapy. The technique was applied in the sitting position to participants. Ischemic compression was performed by compressing trigger points identified by palpation with tolerable intensity using thumb. The duration for each trigger points was 1 minute. Then the muscle containing the trigger point was applied intramuscular stretching for 30 seconds by therapist
Study: NCT03108326

Intervention type: BIOLOGICAL
Intervention: Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra
Description: The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.

Intervention type: BIOLOGICAL
Intervention: Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra
Description: The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
Study: NCT01357525

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:~12 Gy x 3 fractions (36 Gy total)
Study: NCT02975375

Intervention type: PROCEDURE
Intervention: Preoperative geriatric consult or assessment
Description: A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.

Intervention type: PROCEDURE
Intervention: No Preoperative geriatric consult or assessment
Description: No assessment or consult billed in the 4 months before surgery
Study: NCT00614731

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH carrier-protein
Description: KLH carrier-protein vaccination containing no other protein or antibodies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH carrier-protein
Description: KLH carrier-protein vaccination containing no other protein or antibodies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH carrier-protein
Description: KLH carrier-protein vaccination containing no other protein or antibodies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH carrier-protein
Description: KLH carrier-protein vaccination containing no other protein or antibodies
Study: NCT04446104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate Tablets
Description: Hydroxychloroquine tablet 400mg loading dose, followed by 200mg daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 3mg Tab
Description: Ivermectin tablet 12mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc
Description: Zinc tablet 80 mg/vitamin C 500mg daily for 42 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone-iodine throat spray (3 times daily) for 42 days

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Vitamin C tablet 500mg daily for 42 days
Study: NCT00991016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04805712
Description: ascending single and multiple doses starting at 30 mg
Study: NCT04554680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabrafenib and trametinib
Description: Participants will receive systemic therapy in the form of oral tablet dabrafenib 150mg twice a day \& oral tablet trametinib 2mg once a day for 1 or 4 weeks.~Pre- \& post-systemic therapy assessment of tumor iodine absorption is done using I-124 PET CT scan. Participants are prepared for this scan with intramuscular injection of thyrogen 0.9mg on 2 consequent days, followed by I-124 PET-CT scan over the next 3 days for tumoral lesional dosimetry.~Participants are then started on systemic therapy for 1 week, followed by I-124 PET-CT scan. If at least one tumor site can attain adequate dosimetry, RAI (I-131) treatment under thyrogen stimulation will be considered. Systemic therapy will be stopped 3 days after I-131.~If after 1 week of systemic therapy, tumors do not reach dosimetry criteria, participants will be continued on systemic therapy for a total of 4 weeks duration, followed by I-124 PET-CT scan. If tumor can attain adequate dosimetry, I-131 treatment will be considered.
Study: NCT01574092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of two marketed drugs (irinotecan and cisplatin)
Description: Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
Study: NCT03543878

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flicker
Description: The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flicker
Description: The Flicker intervention is delivered with the GammaSense Stimulation System by Cognito Therapeutics and involves viewing flickering lights at gamma frequency (like a strobe light but faster) to drive gamma oscillations in visual brain areas. The GammaSense Stimulation System is a device consisting of a pair of opaque glasses with a light-emitting diode (LED) illumination on the interior of the glasses. Headphones worn by the user during the stimulation session provide the auditory stimulation. When activated for the treatment session, the device will generate light and sound oscillations at 40 cycles per second (Hz) for 60 minutes. Participants will use the device daily during their active treatment period.
Study: NCT03708276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My MS Toolkit
Description: My MS Toolkit, a web-based self-management intervention designed to help persons with Multiple Sclerosis self-manage fatigue, pain, and depressed mood.
Study: NCT02748083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
Study: NCT03604406

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Zoster Vaccine
Description: live-attenuated vaccine to prevent herpes zoster

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Saline solution injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: Saline solution injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Zoster Vaccine
Description: non-live vaccine to prevent herpes zoster
Study: NCT03708614

Intervention type: OTHER
Group type: OTHER
Intervention: Controlled energy diet with elevated protein intake
Description: Participants will be counseled to elevate protein and control energy intake for ten consecutive weeks. Protein intake will be increased in the range of 20-30% of total daily caloric intake. Each participant's diet will also be modified to implement controlled energy intake. Controlled energy intake will be defined as being isocaloric with the participant's current dietary intake.
Study: NCT03244332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting Clinical Data
Description: Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting Clinical Data
Description: Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting laboratory data
Description: Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collecting laboratory data
Description: Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
Study: NCT01293734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum
Description: warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum
Description: clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum
Description: securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline Sustained-release Tablets and budesonide suspension
Description: Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
Study: NCT00720915

Intervention type: OTHER
Group type: OTHER
Intervention: Discontinue anticoagulant therapy (Negative d-dimer)
Description: Patients with negative d-dimer discontinue long-term anticoagulant therapy.

Intervention type: OTHER
Group type: OTHER
Intervention: Continue on anticoagulant therapy (positive d-dimer)
Description: Patients with positive d-dimer continue or re-start on anticoagulant therapy
Study: NCT03371069

Intervention type: OTHER
Intervention: users of methylphenidate
Description: Children and adolescents who are users of methylphenidate, 2010 to 2015